Gene Therapy Targeting HIV EntryReport as inadecuate

Gene Therapy Targeting HIV Entry - Download this document for free, or read online. Document in PDF available to download.


Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA


Department of Pathology, Childrens Hospital of Philadelphia, 34th and Civic Center Blvd-5th Floor Main Building, Philadelphia, PA 19104, USA


Author to whom correspondence should be addressed.

Abstract Despite the unquestionable success of antiretroviral therapy ART in the treatment of HIV infection, the cost, need for daily adherence, and HIV-associated morbidities that persist despite ART all underscore the need to develop a cure for HIV. The cure achieved following an allogeneic hematopoietic stem cell transplant HSCT using HIV-resistant cells, and more recently, the report of short-term but sustained, ART-free control of HIV replication following allogeneic HSCT, using HIV susceptible cells, have served to both reignite interest in HIV cure research, and suggest potential mechanisms for a cure. In this review, we highlight some of the obstacles facing HIV cure research today, and explore the roles of gene therapy targeting HIV entry, and allogeneic stem cell transplantation in the development of strategies to cure HIV infection. View Full-Text

Keywords: HIV; gene therapy; HIV cure; HIV entry; HIV reservoir; CCR5 delta 32 HIV; gene therapy; HIV cure; HIV entry; HIV reservoir; CCR5 delta 32

Author: Chuka Didigu 1 and Robert Doms 1,2,*



Related documents